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Abstract
Purpose:  The  goal  of  this  study  was  to  evaluate  the  diagnostic  accuracy  of  a  software  program
that automatically  analyzes  the  liver  surface  to  diagnose  signiﬁcant  ﬁbrosis,  by  comparing  it  to
the subjective  analysis  of  a  radiologist  and  to  transient  elastography  (Fibroscan®).
Patients  and  methods:  One  hundred  fourteen  patients  with  chronic  liver  disease  were  included
in the  study.  They  underwent  liver  biopsy,  FibroScan® and  ultrasonographic  examination  of  the
liver surface.  The  liver  surface  was  analyzed  by  a  software  program  that  gave  a  score  of  surface
irregularities.  This  evaluation  was  compared  to  subjective  analysis  by  a  radiologist  expert  in
liver imaging  and  by  two  general  radiologists.
Results:  Fifty  percent  of  the  patients  had  signiﬁcant  ﬁbrosis  according  to  the  METAVIR  score.
The AUROC  for  the  diagnosis  of  signiﬁcant  ﬁbrosis  by  the  software  program  was  0.80  (95%CI:
0.71—0.87),  which  was  equivalent  (P  =  0.86)  to  that  of  FibroScan® (0.81;  95%CI:  0.71—0.89).
Abbreviations: AUROC, Area under the receiver operating characteristic (ROC) curve; NASH, Non alcoholic steatohepatitis; ROC, Receiver
operating characteristic; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HIV, Human immunodeﬁciency virus; NPV, Negative predictive value;
PPV, Positive predictive value.
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Results  of  the  subjective  analysis  by  the  expert  radiologist  were  poorer  than  those  of  the
software  analysis  (P  =  0.02)  (AUROC  =  0.66;  95%CI:  0.56—0.75).  Interobserver  agreement  among
radiologists  was  poor  (0.25  <  kappa  <  0.37).
Conclusion:  Computer-assisted  liver  surface  analysis  was  better  than  subjective  analysis,  and
similar to  that  of  the  FibroScan®.  This  method  could  be  useful  for  the  diagnosis  of  signiﬁ-
cant ﬁbrosis  in  patients  with  chronic  hepatitis  and  complementary  to  the  other  non-invasive
diagnostic  tests.
©  2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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he  development  of  ﬁbrosis  during  follow-up  of  chronic  liver
isease,  whatever  the  etiology,  is  a  major  prognostic  fac-
or.  Precise  analysis  of  the  stage  of  ﬁbrosis  is  essential  to
etermine  future  management.  Although  liver  biopsy  is  still
onsidered  to  be  the  gold  standard,  it  still  has  numerous
imitations,  in  particular  due  to  sampling  errors.  The  rate
f  false  negative  ﬁndings  for  the  diagnosis  of  cirrhosis  can
each  up  to  20  to  30%  [1,2].  Moreover,  biopsy  is  invasive,
xpensive  [3,4],  and  conveys  a  risk  of  severe  complications
0.4%)  and  even  death  (0.03%)  [5—7].
As  a  result,  multiple  non-invasive  diagnostic  tests  have
een  developed  to  evaluate  the  liver  as  precisely  as  possi-
le,  to  identify  patients  with  signiﬁcant  lesions  that  could
espond  to  treatment  and  to  monitor  disease  progression.
he  most  common  complementary  tools  are  blood  tests,
hich  consist  of  a  combination  of  biological  markers  [8—11]
nd  transient  elastography  (FibroScan®)  to  measure  liver
tiffness  [12—18].  The  morphological  study  of  the  liver  by
onventional  ultrasonography  (US)  is  also  frequently  used  in
aily  clinical  practice  to  conﬁrm  the  diagnosis  of  cirrhosis
4,19,20].  Among  the  different  criteria  used,  liver  surface
nalysis  using  high  resolution  US  helps  diagnose  liver  ﬁbro-
is  and  differentiate  between  the  early  stages  of  ﬁbrosis
21—23].
The  goal  of  this  study  was  to  evaluate  the  diagnostic  accu-
acy  of  a  software  program  that  automatically  analyzes  the
iver  surface  to  diagnose  signiﬁcant  ﬁbrosis,  by  comparing  it
o  the  subjective  analysis  of  a  radiologist  and  to  transient
lastography.
aterials and methods
atients
ne  hundred  fourteen  patients  (56  women,  58  men;  mean
ge  51  ±  10.6  years  old,  range  18—82  years),  presenting
ith  unexplained  persistent  elevation  of  transaminases  or
hronic  liver  disease,  were  included  in  this  prospective
tudy.  One  hundred  and  ﬁve  patients  were  hospitalized  in
he  hepatogastroenterology  unit  of  the  Grenoble  University
ospital  to  undergo  liver  biopsy  and  the  remaining  nine  had
linically  conﬁrmed  cirrhosis.  US-guided  percutaneous  liver
iopsy  was  performed  by  two  hepatologists.  Histological
nalysis  of  the  liver  biopsies  was  performed  by  an  experi-
nced  pathologist.  The  degree  of  liver  ﬁbrosis  was  assessed
sing  the  5  stages  of  the  METAVIR  scoring  system,  from  F0
o  F4  (absent,  minimal,  moderate,  severe  and  conﬁrmed
S
A
Cirrhosis).  The  study  was  consistent  with  the  Declaration  of
elsinki;  data  were  collected  as  part  of  a biological  col-
ection  authorized  by  the  Institutional  Review  board  and
egistered  under  the  reference  DC-2008-727.
maging protocol
ne  hundred  four  patients  had  liver  stiffness  measurement
y  two  trained  operators  using  the  FibroScan® (Echosens,
aris,  France)  US  analysis  of  the  liver  surface  was  performed
y  a  radiologist  using  an  Aplio® (Toshiba  Medical  Systems,
okyo,  Japan)  US  unit  and  a  7.2  MHz  probe  within  between
ne  and  four  hours  after  performing  the  liver  biopsy  or  dur-
ng  a  hospital  stay  in  patients  with  cirrhosis.  US  cine  loops
ere  recorded  for  each  patient  using  a  right  lateral  inter-
ostal  approach.  It  should  be  noted  that  the  choice  was
ade  to  only  analyze  the  right  liver  surface.  Indeed,  the
orrelation  with  the  results  of  liver  biopsy  (also  performed
n  the  right  liver)  appeared  more  pertinent.  Moreover,  data
rom  the  expert  radiologist,  in  addition  to  preliminary  tests
erformed  with  the  software,  showed  that  the  quality  of
he  US  recordings  of  the  left  liver  surface  were  often  insufﬁ-
ient  for  reliable  analysis  of  regularity  because  of  the  deeper
ocation  and  higher  slant  of  the  left  liver  capsule.
mage analysis
n  extract  of  each  video  recording  was  selected  by  the  oper-
tor  by  positioning  a  region  of  interest  outside  of  areas
f  poor  echogenicity,  areas  with  artifacts  due  to  shad-
wing  posterior  to  the  ribs  or  areas  where  the  capsule
id  not  appear  perpendicular  to  the  US  beam.  The  video
xtracts  were  read  by  a  radiologist  expert  specialized  in
iver  imaging  and  two  general  radiologists.  Interpretations
ere  performed  blinded  to  clinical  data  and  histopatholog-
cal  results.  A  score  of  0  to  4  was  used:  0  for  a  smooth,  thin
nd  regular  hyperechogenic  surface,  1  for  a  nearly  normal
urface  with  some  irregularities,  2  intermediate,  3  for  an
rregular  spotty  surface,  and  4  for  a  totally  irregular  and
eformed  liver  surface.
These  video  extracts  were  then  analyzed  using  soft-
are  developed  at  the  Grenoble  University  Hospital  allowing
utomated  analysis  of  the  contours  of  the  liver  surface  by
S.  This  software  quantitatively  evaluated  the  irregularity
f  the  liver  surface  using  a  score  between  0  and  100%  (Fig.  1).tatistical analysis
ll  data  were  recorded  and  analyzed  using  NCSS  and  Med-
alc  software.  The  reference  test  was  the  histopathological
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Figure 1. Analysis of the liver surface with high resolution ultrasonography using software that automatically identiﬁes the interface
between the liver capsule and the liver parenchyma (red line). The software then calculates an irregularity score by comparing this line
ETAVIR F0). The irregularity score calculated by the software = 17%. (b)
Figure 2. Distribution of scores of liver surface irregularity in
relation to the stage of ﬁbrosis.with an ‘‘ideal’’ regular and continuous contour. (a) Normal liver (M
Cirrhotic liver (METAVIR F4). The calculated score = 50%.
analysis  of  liver  tissue  samples.  The  results  of  the  software
analysis,  of  FibroScan® and  of  the  radiologist  interpretations
for  the  diagnosis  of  signiﬁcant  ﬁbrosis  (F0-1  vs.  F2-4),  severe
ﬁbrosis  (F0-2  vs.  F3-4)  and  cirrhosis  (F0-3  vs.  F4)  were  eval-
uated  using  area  under  the  ROC  curve  (AUROC)  analysis.  A  P
value  less  than  0.05  was  considered  statistically  signiﬁcant.
The  sensitivity,  speciﬁcity,  positive  predictive  value  (PPV)
and  negative  predictive  value  (NPV)  were  calculated  after
determining  optimal  threshold  values  for  each  method.
Correlations  between  liver  surface  irregularity  scores
(using  software)  and  results  of  histopathological  analysis
were  evaluated  by  a  non-parametric  Spearman’s  correla-
tion  coefﬁcient  ().  The  kappa  test  was  used  to  evaluate
interobserver  agreement  of  radiologists  for  the  diagnosis  of
signiﬁcant  ﬁbrosis.
Results
The  distribution  of  patients  in  relation  to  the  stage  of  ﬁbro-
sis  and  etiology  is  shown  in  Table  1.  Fifty  percent  of  the
patients  had  signiﬁcant  ﬁbrosis  F  ≥  2.  The  quality  of  110/114
US  videos  (96.5%)  was  considered  to  be  good  enough  for
automatic  software  analysis.  The  4  other  ultrasound  videos
were  automatically  rejected  as  failures  by  the  software,
because  the  slant  of  the  capsule  was  detected  as  too  high
in  relation  to  the  axis  of  the  ultrasound  beam.
The  scores  of  surface  irregularity  according  to  the  soft-
ware  were  between  11%  and  89%  (Fig.  2).  They  were
signiﬁcantly  correlated  to  the  degree  of  ﬁbrosis  (  =  0.508;
P  <  0.001).  The  results  of  the  software  for  the  diagnosis
of  signiﬁcant  ﬁbrosis  evaluated  by  the  AUROC  were  0.80
(95%CI:  0.71—0.87).  A  threshold  of  25%  resulted  in  a  sen-
sitivity  of  89%  and  a  speciﬁcity  of  61%.  With  a  score  below
25%,  observed  in  37%  of  the  population,  signiﬁcant  ﬁbrosis
was  excluded  with  a  NPV  of  85.4%.The  AUROC  for  the  diagnosis  of  signiﬁcant  ﬁbrosis  by
the  expert  radiologist  was  0.66  (95%CI:  0.56—0.75).  Diag-
nosis  by  the  expert  radiologist  appeared  to  be  signiﬁcantly
poorer  (P  =  0.02)  than  by  the  software  (Fig.  3).  If  a  subjective
Figure 3. Comparison of ROC curves for the software
(AUROC = 0.80), FibroScan® (AUROC = 0.81) and the expert
(AUROC = 0.66) for the diagnosis of signiﬁcant ﬁbrosis.
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Table  1  Distribution  of  patients  in  terms  of  chronic
liver  disease  and  the  stage  of  ﬁbrosis  according  to  the
METAVIR  score.
METAVIR  score
F0  F1  F2  F3  F4  Total
HCV  0  17  19  8  8  52
HBV  6  15  1  2  0  24
Autoimmune
hepatitis
0 5  2  0  0  7
NASH  3  1  1  0  0  5
Hemochromatosis  0  0  1  2  0  3
Sclerosing
cholangitis
0  1  1  1  1  4
Primary  biliary
cirrhosis
0 1  0  1  1  3
Alcohol  0  0  0  0  8  8
Miscellaneous  6  2  0  0  0  8
Total 15  42  25  14  18  114
Miscellaneous contains abnormal liver test results, sclerodermia,
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aportal thrombosis.
adiological  score  of  ≥  2  was  chosen  to  indicate  signiﬁcant
brosis,  the  diagnosis  would  be  made  with  a  sensitivity  of
6%  and  a  speciﬁcity  of  54%.  Moreover,  the  interobserver
greement  among  the  radiologists  was  poor,  with  kappa
oefﬁcients  ranging  between  0.25  and  0.37.
The  AUROC  for  the  diagnosis  of  signiﬁcant  ﬁbrosis  by
ibroScan® was  0.81  (95%CI:  0.71—0.89),  with  no  signiﬁcant
ifference  with  that  obtained  using  the  software  (P  =  0.86).
Comparison  of  AUROCs  obtained  using  software,
ibroScan® and  subjective  analysis  of  the  expert  radiologist
or  the  different  stages  of  ﬁbrosis  is  presented  in  Table  2.
iscussion
he  results  of  our  study  show  that  automatic  liver  surface
nalysis  is  better  than  subjective  analysis  by  radiologists.
ur  results  show  that  the  diagnosis  of  signiﬁcant  ﬁbrosis
y  subjective  radiological  interpretation  is  not  satisfactory.
oreover,  as  might  be  expected  with  the  subjective  eval-
ation,  agreement  among  radiologists  is  poor.  The  results
btained  with  the  software  are  similar  to  those  of  FibroScan®
or  all  stages  of  ﬁbrosis  and  are  better  than  those  reached
y  the  expert  radiologist  (Table  2).  The  diagnostic  accuracy
f  the  software  was  signiﬁcantly  better  than  those  of  the
xpert  for  F  ≥  2  ﬁbrosis  (P  =  0.02).  Indeed,  although  there
ere  numerous  areas  of  overlap  between  the  scores  of  liver
rregularity  by  the  software  and  the  METAVIR  score  (Fig.  2),
he  discriminatory  value  of  the  software  appears  to  be  espe-
ially  effective  between  the  two  groups  corresponding  to
igniﬁcant  ﬁbrosis  (F2-F3-F4)  and  minimal/absent  ﬁbrosis
F0-F1).
Thus,  the  overall  results  of  the  software  for  the  evalua-
ion  of  signiﬁcant  ﬁbrosis  are  good  with  an  AUROC  of  0.80.
hese  results  are  basically  similar  to  those  of  other  con-
entional  tests  in  the  literature  with  an  AUROC  of  0.84  for
ibroScan® [13]  and  between  0.78  and  0.86  for  the  main
t
b
a
sN.  Huet  et  al.
iological  tests  [9,10]. FibroScan® and  the  biological  tests
re  alternative  tests  that  are  increasingly  used  and  some  of
hem  have  been  validated  in  the  diagnosis  of  HCV-related
brosis  or  cirrhosis  [16,19].
The  software  would  be  extremely  useful  if  it  were  inte-
rated  into  an  US  equipment  to  be  used  in  routine  clinical
ractice.  The  analysis  could  be  performed  during  morpho-
ogical  liver  US  examination,  which  is  part  of  the  initial  work
p  for  all  patients  with  chronic  liver  disease,  or  even  more
idely  for  screening  during  US  for  any  indication.  However,
t  a  threshold  of  25%,  the  software  would  not  have  detected
igniﬁcant  ﬁbrosis  present  in  two  patients.  According  to  the
hree  readers,  the  capsule  in  these  recordings  appeared  thin
nd  regular  with  no  breaks  or  marked  deformity.  These  fea-
ures  therefore  result  in  a  false  negative  ﬁnding  of  liver
urface  analysis  rather  than  of  the  software.  The  study  by
olli  et  al.  reported  false  negatives  in  26%  of  F3-F4  patients
ithout  any  explanation  for  this  [22].  Nevertheless,  the
arenchyma  in  our  two  false  negatives  was  multinodular,  a
eature  that  is  not  studied  by  the  software  but  that  could
llow  the  radiologist  to  reclassify  these  patients.
The  potential  causes  of  ﬁbrosis  stage  overestimation
ere  searched  for  in  twenty  F0-F1  patients  in  our  study.
igniﬁcant  fragmentation  of  the  biopsy  samples  could  have
nﬂuenced  the  level  of  disagreement  because  they  were
ound  in  50%  of  the  overestimated  F0-F1  patients  compared
o  13.4%  of  the  patients  for  whom  there  was  agreement.
he  fragmentation  of  the  biopsy  could  result  in  a  false  neg-
tive  biopsy,  rather  than  a  false  positive  US  analysis.  On  the
ther  hand,  the  presence  of  biopsy  specimens  that  were
oo  small  with  too  few  portal  spaces  did  not  seem  to  be
 factor  of  disagreement.  Finally,  steatosis  could  play  a  role
ecause  the  degree  of  ﬁbrosis  was  overestimated  in  3/4
f  patients  with  NASH  in  our  study  [23,24].  The  degree  of
brosis  was  also  overestimated  in  these  patients  by  most
f  our  radiologists  and  in  all  patients  by  the  expert  reader.
erisinusoidal  ﬁbrosis  without  portal  or  periportal  involve-
ent,  which  is  therefore  not  taken  into  account  in  the
ETAVIR  score,  is  often  associated  with  steatohepatitis  [24]
nd  could  play  a  role  in  the  development  of  capsular  irreg-
larities,  especially  since  it  was  more  present  in  the  F0-F1
verestimated  patients  than  in  those  for  whom  there  was
greement.
The  number  of  false  positive  and  false  negative  ﬁnd-
ngs  with  this  diagnostic  method  are  therefore  similar  to
hose  obtained  with  other  available  tests.  However,  it  has
he  advantage  of  having  a  different  performance  proﬁle.
ndeed,  there  is  usually  a  peak  rate  of  disagreement  in  F2
atients,  which  is  due  to  the  difﬁculty  of  classifying  this
roup  by  usual  non-invasive  methods.  In  our  study  on  the
ther  hand,  82.6%  of  the  F2  patients  were  correctly  classi-
ed.
Four  failures  were  automatically  identiﬁed  by  the  soft-
are  because  of  the  high  slant  between  the  liver  capsule
nd  the  US  beam  axis.  The  110  other  US  recordings  were
ccepted  and  analyzed  by  the  software.  The  liver  surface  is
sually  located  superﬁcially  and  is  therefore  easy  to  evalu-
te  with  a  7.2  MHz  probe.  Unlike  FibroScan®, we  can  assume
hat  ascites  does  not  inﬂuence  the  success  of  this  technique
ecause  it  does  not  limit  the  effectiveness  of  the  US  beam
nd  does  not  prevent  satisfactory  visualization  of  the  cap-
ule.  On  the  other  hand,  when  the  liver  is  located  deeper
Ultrasonographic  assessment  of  liver  ﬁbrosis  with  computer-assisted  analysis  945
Table  2  Areas  under  the  ROC  curves  of  FibroScan®, the  software  and  the  expert  radiologist  for  the  diagnosis  of  ﬁbrosis
in  relation  to  the  METAVIR  stage.
Signiﬁcant  ﬁbrosis
(F0-1  vs.  F2-3-4)
Severe  ﬁbrosis
(F0-1-2  vs.  F3-4)
Cirrhosis
(F0-1-2-3  vs  F4)
AUROC  95%CI  AUROC  95%CI  AUROC  95%CI
FibroScan® 0.81 0.71—0.89 0.80 0.70—0.88 0.84  0.75—0.91
Automatic  software  analysis  0.80  0.71—0.87  0.76  0.67—0.85  0.81  0.72—0.88
Expert  reader  0.66  0.56—0.75  0.70  0.61—0.78  0.70  0.61—0.79
The differences in AUROC observed between FibroScan® and the automatic software analysis were not signiﬁcant. The AUROC of the
software was higher than those of the expert; the threshold of signiﬁcance was reached for the diagnosis of signiﬁcant ﬁbrosis (P = 0.02).
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Rbelow  the  skin  (i.e.,  more  than  2  cm),  ultrasound  visual-
ization  of  the  liver  surface  may  be  less  precise  and  it  is
possible  that  the  evaluation  of  surface  regularity  will  be
less  accurate.  This  hypothesis  should  be  conﬁrmed  by  a sub-
group  evaluation  in  a  further  study  with  a  sufﬁciently  large
proportion  of  over  weighted  patients.
Our  study  has  several  limitations.  The  evaluation  of  this
technique,  like  all  non-invasive  diagnostic  techniques  of
liver  ﬁbrosis,  was  limited  by  the  absence  of  a  strong  standard
of  reference.  It  is  acknowledged  that  a  biopsy  fragment  of
25  mm  in  length,  which  corresponds  to  the  reference  size,  is
associated  with  a  rate  of  disagreement  of  25%  for  the  degree
of  ﬁbrosis  because  of  possible  heterogeneous  distribution  of
ﬁbrosis  in  the  liver  [25].
The  interobserver  variability  of  this  technique  was  not
studied  because  it  was  not  possible  for  each  patient  to
undergo  two  US  examinations  by  two  different  radiolo-
gists  on  the  day  of  the  biopsy.  To  evaluate  intra-operator
variability  the  different  patients  would  have  needed  to
return  to  a  consultation  after  a  short  period,  which  was
not  possible  for  organizational  reasons.  There  is  however
a  factor  of  potential  variability  that  seems  important  to
analyze:  the  extent  of  the  liver  surface  that  was  evalu-
ated  varied  from  patient  to  patient  depending  on  the  US
scanning  performed,  and  the  irregularities  of  the  liver  cap-
sule  could  be  different  depending  on  the  parts  of  the  liver
that  were  explored.  Thus,  these  preliminary  results  must
be  conﬁrmed  by  further  studies  in  which  the  inﬂuence  of
different  US  parameters,  the  analyzed  area  and  the  opera-
tor  can  be  identiﬁed.  If  the  software  was  included  directly
in  the  US  machine,  testing  could  be  performed  more  sim-
ply  by  different  radiologists  on  the  same  patient  during
an  US  examination  or  several  days  before  or  after  the
biopsy.
Moreover,  it  is  impossible  to  draw  ﬁrm  conclusions  from
this  preliminary  study  on  the  value  of  this  liver  surface  anal-
ysis  technique  compared  to  existing  tests,  and  on  the  role  it
could  play.  Additional  studies  are  needed  to  further  deﬁne
the  value  of  this  approach  and  to  compare  it  with  other
tests  to  deﬁne  the  best  diagnostic  thresholds  and  possible
test  combinations.Conclusion
This  computer-assisted  analysis  of  the  liver  surface  showed
a  better  accuracy  than  subjective  analysis  by  radiologists,ith  similar  performance  to  FibroScan® for  the  diagnosis
f  signiﬁcant  ﬁbrosis.  The  reproducibility  of  this  technique
s  well  as  its  value  in  association  with  other  non-invasive
iagnostic  tests  should  be  evaluated  in  larger  studies.
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